RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs

Sarah Bajan; Gyorgy Hutvagner

doi:10.3390/cells9010137

Back

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs

Journal article

Open access

Peer reviewed

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs

Sarah Bajan and Gyorgy Hutvagner

Cells, Vol.9(1), 137

2020

DOI: https://doi.org/10.3390/cells9010137

Files and links (2)

pdf

PDF - Published Version (Open Access)1.54 MBDownload View

Published VersionCC BY V4.0, Open Access

url

https://doi.org/10.3390/cells9010137View

Published Version

Abstract

miRNA

RNAi

drug delivery

Rna therapeutics

antisense RNA

The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in 1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was United States Food and Drug Administration (FDA) approved. This promises to be a rapidly expanding market, as many emerging biopharmaceutical companies are developing RNA interference (RNAi)-based, and RNA-based antisense oligonucleotide therapies. However, miRNA therapeutics are noticeably absent. miRNAs are regulatory RNAs that regulate gene expression. In disease states, the expression of many miRNAs is measurably altered. The potential of miRNAs as therapies and therapeutic targets has long been discussed and in the context of a wide variety of infections and diseases. Despite the great number of studies identifying miRNAs as potential therapeutic targets, only a handful of miRNA-targeting drugs (mimics or inhibitors) have entered clinical trials. In this review, we will discuss whether the investment in finding potential miRNA therapeutic targets has yielded feasible and practicable results, the benefits and obstacles of miRNAs as therapeutic targets, and the potential future of the field.

Details

Title: RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Authors: Sarah Bajan (Author) - University of the Sunshine Coast, Queensland, School of Health and Sport Sciences - Legacy
Gyorgy Hutvagner (Author) - University of Technology Sydney
Publication details: Cells, Vol.9(1), 137; 27
Publisher: MDPI AG
Date published: 2020
DOI: 10.3390/cells9010137
ISSN: 2073-4409
Copyright note: Copyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Organisation Unit: School of Health - Biomedicine; University of the Sunshine Coast, Queensland; School of Health and Sport Sciences - Legacy; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99451327502621
Output Type: Journal article

Metrics

9 File views/ downloads

60 Record Views

316 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Highly Cited Paper

Collaboration types: Domestic collaboration
Web Of Science research areas: Cell Biology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites